Ambry Genetics Initiates Fluidigm Corporation-Based Genomic Research Services for Gene Expression, SNP Genotyping and Sample Prep for Targeted Sequencing  
4/12/2012 10:17:56 AM

ALISO VIEJO, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced today the launch of Fluidigm (NASDAQ:FLDM) BioMark™ HD and Access Array™ System-based genomic research services. These services provide gene expression, SNP genotyping, and sample preparation for targeted sequencing using next-generation sequencers, focused on the genomics research market.